Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corporativo FraguaB de CV's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2024 was $232 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was $232 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Corporativo FraguaB de CV's annualizedROC % for the quarter that ended in Dec. 2024 was 11.30%.
Corporativo FraguaB de CV's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 19.45%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Corporativo FraguaB de CV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 9.39%.
Corporativo FraguaB de CV (OTCPK:CGSBF) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Corporativo FraguaB de CV's annualizedROC % for the quarter that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corporativo FraguaB de CV EBIT Competitor Comparison
For the Pharmaceutical Retailers subindustry, Corporativo FraguaB de CV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corporativo FraguaB de CV EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Corporativo FraguaB de CV's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Corporativo FraguaB de CV's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $232 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corporativo FraguaB de CV (CGSBF) has a EBIT of $232 Mil as of Dec. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corporativo FraguaB de CV.
Is Corporativo FraguaB de CV's EBIT too high?
Corporativo FraguaB de CV's current EBIT is $232 Mil. Overall, Corporativo FraguaB de CV has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Corporativo FraguaB de CV's EBIT compare to competitors?
Corporativo FraguaB de CV's EBIT of $232 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corporativo FraguaB de CV. Corporativo FraguaB de CV's current EBIT is $232 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corporativo FraguaB de CV stock overvalued right now?
Corporativo FraguaB de CV (CGSBF) has a current EBIT of $232 Mil. The stock's GF Value™ is $44.58, compared to a current price of $29.66 — trading 33.5% below its estimated fair value. The current EBIT is $232 Mil. Corporativo FraguaB de CV's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Corporativo FraguaB de CV (CGSBF), the current EBIT is $232 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corporativo FraguaB de CV (CGSBF) Overvalued in 2026?
Based on GuruFocus' analysis, Corporativo FraguaB de CV stock appears to be undervalued.
The current stock price of $29.66 is trading 33.5% below its estimated GF Value™ of $44.58.
Key valuation signals for CGSBF:
EBIT: $232 Mil
GF Value™: $44.58 vs. price of $29.66 (33.5% below fair value)
No single metric tells the full story. See the CGSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corporativo Fragua SAB de CV is engaged in the drug retail sector in Mexico. The company operates a network of pharmacies under the SuperFarmacia brand name, focusing on selling medicines, medical devices, and a variety of other products, including grocery items, exercise machines, perfumes, housewares, electronics, personal care products, toys, and photographic equipment.
84GF Score
Get the complete analysis for CGSBF
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGSBF has been successfully added to your 
